Martin Reck

17PUBLICATIONS
148CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Jul 27, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.

Enriqueta Felip, Nasser Altorki, Caicun Zhou

|Mar 02, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial.

Horst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall

|Apr 26, 2024
Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations.

Nikolaj Frost, Martin Reck

|Nov 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.

Charles M Rudin, Stephen V Liu, Ross A Soo

Pageof 3

Frequent Collaborators

4 joint publications

Enriqueta Felip

4 joint publications

Luis Paz-Ares

4 joint publications

Melissa L Johnson

3 joint publications

Ticiana Leal